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Abstract
Background: Cardiovascular disease (CVD) carries a high burden of morbidity and mortality and
is associated with significant utilization of health care resources, especially in the elderly. Numerous
randomized trials have established the efficacy of cholesterol reduction with statin medications in
decreasing mortality in high-risk populations. However, it is not known what the effect of the
utilization of these medications in complex older adults has had on mortality and on the utilization
of health services, such as physician visits, hospitalizations or cardiovascular procedures.
Methods:  This project linked clinical and hospital data from the Improving Cardiovascular
Outcomes in Nova Scotia (ICONS) database with administrative data from the Population Health
Research Unit to identify all older adults hospitalized with ischemic heart disease between October
15, 1997 and March 31, 2001. All patients were followed for at least one year or until death.
Multiple regression techniques, including Cox proportional hazards models and generalized linear
models were employed to compare health services utilization and mortality for statin users and
non-statin users.
Results: Of 4232 older adults discharged alive from the hospital, 1629 (38%) received a statin after
discharge. In multivariate models after adjustment for demographic and clinical characteristics, and
propensity score, statins were associated with a 26% reduction in all- cause mortality (hazard ratio
(HR) 0.74, 95% confidence interval (CI) 0.63-0.88). However, statin use was not associated with
subsequent reductions in health service utilization, including re-hospitalizations (HR, 0.98, 95% CI
0.91-1.06), physician visits (relative risk (RR) 0.97, 95% CI 0.92-1.02) or coronary revascularization
procedures (HR 1.15, 95% CI 0.97-1.36).
Conclusion: As the utilization of statins continues to grow, their impact on the health care system
will continue to be important. Future studies are needed to continue to ensure that those who
would realize significant benefit from the medication receive it.
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Background
Although mortality from cardiovascular disease (CVD)
has been decreasing steadily in Canada, it is still the lead-
ing cause of death, accounting for 33% of all mortality in
2003 [1-3]. Patients with CVD have a high burden of mor-
bidity and utilize significant health care resources, result-
ing in high health care costs. In 1998, CVD represented
the most costly diagnostic category, accounting for a total
cost of $18.5 billion in Canada (11.6% of total costs of all
illnesses) [3,4].
In several randomized controlled trials (RCTs) [5-12], the
use of statins has been shown to substantially reduce the
occurrence of morbidity and mortality in people with cor-
onary artery disease. Consistent treatment effects across
multiple groups, including older adults [13-17] have been
demonstrated. The evidence on the efficacy of statins from
these RCTs has led to widespread use of these medications
in all age groups [18-20].
Gaps in evidence may exist on the safety and effectiveness
of drugs during real world use where drugs may be often
used by diverse patient groups outside the controlled
environment of clinical trials [21-23]. In particular, older
adults who may have many concomitant diseases, com-
plex drug regimens and cognitive and functional decline
are often excluded from RCTs; this may limit the general-
izability of RCTs to these populations. Therefore, the
impact of statins on mortality and health service utiliza-
tion in the real world in older adults may need to be
explored.
The purpose of this study was to determine if older adults
who received statins after discharge from hospital would
have better health outcomes (less use of health services
and decreased mortality) compared to those who did not
receive statins.
Methods
Data Sources
The Improving Cardiovascular Outcomes in Nova Sco-
tians (ICONS) project was a multi-stakeholder, province-
wide initiative that first enrolled patients on October 15,
1997 [24]. It includes a registry of all patients in Nova Sco-
tia, Canada hospitalized with a diagnosis of ischemic
heart disease (IHD), congestive heart failure or atrial
fibrillation [25]. Data for the ICONS study was retrospec-
tively abstracted from patient charts; variables include
patient demographics, laboratory and diagnostic tests,
social history, cardiovascular risk factors, medical history,
in-hospital cardiovascular procedures and admission and
discharge medications.
The Population Health Research Unit (PHRU), Dalhousie
University, houses population-level administrative health
data for the province of Nova Scotia [26]. The data repos-
itory contains comprehensive information about insured
health services delivered to residents of Nova Scotia from
1989 onward. The databases at PHRU contain informa-
tion on vital statistics, physician billings, hospitalizations
and all prescriptions dispensed to eligible adults 65 years
and over registered in the Nova Scotia Pharmacare Pro-
gram.
Study Cohort and Design
A retrospective cohort design was used. The study popula-
tion included all individuals ≥ 66 years old registered in
the Nova Scotia Seniors Pharmacare Program (NSSPP)
who were discharged alive from hospital in Nova Scotia,
Canada between October 15, 1997 and March 31, 2001,
with a diagnosis of IHD. The NSSPP is a publicly funded
drug insurance plan that reimburses drugs and medical
supplies listed in the Nova Scotia Formulary for entitled
seniors in the province. The beneficiaries of this program
are seniors with a minimum age of 65 years who enrolled
in the program by paying the required insurance premium
and the co-payments. The NSSPP does not provide cover-
age for senior residents who have private drug insurance,
benefit coverage with Veterans Affairs Canada or First
Nations and Inuit Health. Approximately 85% of seniors
in Nova Scotia are eligible beneficiaries under the NSSPP;
the remainder of the senior population has drug coverage
under private or Federal programs (Data on file, Popula-
tion Health Research Unit, Dalhousie University).
Patients were followed for at least one year or until death;
if a patient had more than one hospital admission during
the study period, the first hospitalization date was used as
the index hospitalization. This study received approval
from the Research Ethics Board of the Capital Health Dis-
trict Health Authority, Halifax, Nova Scotia.
Measures of Outcomes and Exposures
The primary outcome of interest was defined as the utili-
zation of health services (physician services, hospitaliza-
tions, or a coronary revascularization procedure) after the
index discharge from hospital with IHD, and within the
follow-up period (to March 31, 2002 or death). The sec-
ondary outcome measure was all-cause mortality after the
index hospitalization.
The primary exposure of interest was the dispensing of at
least one prescription for a statin medication after dis-
charge from hospital as identified through the Nova Sco-
tia Pharmacare databases. Non-initiators of statin
medications were defined as those patients receiving no
statin prescriptions for at least one year before hospital
admission and throughout the study period. New initia-
tors of statin medications were defined as those patients
who received at least one prescription for a statin after
hospital discharge. Statins were identified using DrugBMC Health Services Research 2009, 9:198 http://www.biomedcentral.com/1472-6963/9/198
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Identification Numbers (DINs), a Canadian system used
to identify unique drug products and through the Ana-
tomical Therapeutic Chemical (ATC) classification system
[27,28].
Statistical Analysis
Descriptive Analysis
Descriptive statistics were used to compare baseline
patient characteristics between groups using chi-squared
tests for categorical variables and Student t-tests for con-
tinuous variables. Bivariate associations were examined
with Mantel Haenszel summary odds ratios to determine
possible interactions or effect modification between statin
therapy, mortality and age or gender. No age or gender
interactions were identified.
The number of distinct medications prescribed in the pre-
vious year (NODMP) is one method used to adjust for co-
morbidity in administrative database studies [29-36]. As
the NODMP is easy to access and calculate and has been
validated [33,35,37-39], and as health service utilization
was the primary outcome measure for this project, the
NODMP was used as the method to adjust for co-morbid-
ity.
Propensity Model
In observational studies, there is no control over treat-
ment and the exposed and unexposed groups may have
large differences in their observed covariates, which lead
to biased estimates of treatment effects [40,41]. Propen-
sity analysis attempts to identify patients who are similar
except for their treatment assignment to approximate the
conditions of a randomized controlled trial [40-44].
A multivariate logistic regression model was generated to
estimate for each patient the propensity to receive a statin
after discharge from hospital. Available clinical, demo-
graphic and treatment variables were incorporated into
the model. The variables included in the propensity score
model are listed in Table 1. The ability of the model to dis-
Table 1: List of Variables entered into the Propensity Model and their Description
Variable Measure Source
Outcomes and Exposures
Physician Visits Continuous PHRU physician services database
Hospitalizations Continuous PHRU hospitalization database
Coronary Re-vascularizaton Continuous ICONS (Inpatient chart)
Mortality Yes/No ICONS (Vital Statistics)
Demographics
Age Continuous
Categorical: 66-75, 75-80, >80 (by tertiles)
PHRU (Pharmacare database)
Gender Male, Female ICONS (Inpatient chart)
Region of Province where Patient Resides Northern, Eastern, Western, Southern ICONS (Inpatient chart)
Risk Factors
Total blood cholesterol measured in hospital Yes/No ICONS (Inpatient chart)
LDL cholesterol measured in hospital Yes/No ICONS (Inpatient chart)
HDL cholesterol measured in hospital Yes/No ICONS (Inpatient chart)
Triglycerides measured in hospital Yes/No ICONS (Inpatient chart)
Diabetes Yes/No ICONS (Patient reported)
Hypertension Yes/No ICONS (Patient reported)
Smoking Past, Current, Never ICONS (Patient reported)
Family History of CVD Yes/No ICONS (Patient reported)
Previous PTCA Yes/No ICONS (Patient reported)
Previous CABG Yes/No ICONS (Patient reported)
Previous CHF Yes/No ICONS (Patient reported)
Previous Cardiac Catheterization Yes/No ICONS (Patient reported)
Previous Myocardial Infarction Yes/No ICONS (Patient reported)
Previous stroke Yes/No ICONS (Patient reported)
Previous TIA Yes/No ICONS (Patient reported)
Year of Entry into study By Quartiles ICONS (Inpatient chart)
Number of distinct prescription medications in 6 months pre-
hospitalization
Continuous
Categorical: <3, 3-<6, 6-<9, ∃ 9 (by quartiles)
PHRU Pharmacare database
In-hospital clinical data
Discharge diagnosis UA/AMI ICONS (Health Records)
In-hospital procedures 
(PTCA, CABG, EST, Cardiac catheterization)
Yes/No ICONS (Inpatient Chart)
Medications on discharge 
(ASA, Beta-blockers, CCB, ACE, Fibrates)
Yes/No ICONS (Inpatient Chart)BMC Health Services Research 2009, 9:198 http://www.biomedcentral.com/1472-6963/9/198
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criminate between patients who did and did not receive
statin therapy was assessed with the c-statistic. The study
population was divided into quintiles of increasing prob-
ability for statin initiation, and the propensity score was
entered by quintile level into the final multivariate regres-
sion models used to determine the relationship between
statins and the outcomes of interest [41-44].
Multivariate Analysis
Once propensity scores had been estimated for each
patient, the scores were sorted in ascending order, and
then stratified into quintiles. Propensity scores by quin-
tiles were fairly well matched between statin initiators and
non-initiators. As the goal of stratification is to remove
differences in covariates between the two groups, covari-
ates were examined within each quintile for statin initia-
tors and non-initiators to ensure that the two groups were
well matched for each covariate; any variables that were
not balanced within a quintile were included in the final
multivariate models as first order interaction terms. Other
variables forced into the final multivariate models
included age and gender.
We determined the impact of the number and rate of re-
hospitalizations using generalized linear models (GLM)
and Cox proportional hazards models. GLM was also
used to examine the relationship between statins and the
number of physician services per person. The negative
binomial distribution was used in the GLM models as the
Poisson assumption was violated. Cox proportional haz-
ards models were used to estimate the HR and 95% CI for
the association between coronary revascularizations stat-
ins and mortality and statins. All multivariate analyses
were undertaken both with and without propensity
adjustment.
All statistical analysis was undertaken using the SAS statis-
tical computer program version 8.2 [45] and models were
developed using a non-automated, backwards selection
process.
Results
Baseline Characteristics
The study population consisted of 4232 older adults dis-
charged alive from the hospital with a diagnosis of IHD
between October 15, 1997 and March 31, 2001. The mean
age was 77.5 years (± 7 years), and 48% (n = 2036) were
male. A total of 38% of patients (n = 1629) were dis-
pensed a statin during the study period. Overall, patients
were followed for an average of 28.0 (± 14.6 months)
months from discharge, during which time 26% of
patients (n = 1120) died. The percentage of those receiv-
ing statins remained relatively stable over the study
period, with annual rates of utilization of 39.1%, 38.8%,
37.7% and 38.4% (p = 0.92). Over 50% (52.7%) of
patients received their first statin prescription within 30
days of hospital discharge, 19.5% of patients received
their first prescription for a statin within 90 days of dis-
charge, 17.4% within 365 days, and 10.4% received the
first statin prescription 365 days after discharge.
The demographic and clinical characteristics of the 4232
patients in the cohort are described in Table 2. There were
notable differences between statin initiators and non-ini-
tiators. On index hospital admission, statin initiators
seemed healthier in that they were younger, less often had
a history of a CVD, and had fewer prescription medica-
tions dispensed in the six months pre-hospitalization.
However, they were more likely to be current smokers and
to have a family history for CVD. During the index hospi-
talization, statin initiators more often received a coronary
revascularization procedure, and were more often pre-
scribed cardiovascular medications on discharge. The c-
statistic for the propensity model was 0.78, indicating that
the propensity model discriminated acceptably between
patients receiving a statin on discharge and those who did
not [44]. A model with a c-statistic of 0.5 would reflect a
completely random prediction model, while a model that
discriminates perfectly between patients with and without
an event would have a c-statistic of 1.0.
Impact of Statins on Health Services Utilization
Although the percentage of older adults re-admitted to the
hospital for any cause was decreased by 16% (HR 0.84,
95% CI 0.78-0.90) before propensity adjustment, this
beneficial effect disappeared once propensity scores were
incorporated into the model (Table 3). Adjusting for pro-
pensity score resulted in a similar trend for the impact of
statins on the percent of those with CVD-related re-hospi-
talizations. Before propensity adjustment, statins had no
impact on CVD-related re-hospitalization rates in older
adults; however, after propensity adjustment there was an
11% increase those with CVD-related re-hospitalizations
(HR 1.11, 95% CI 1.02-1.22). The number of all-cause re-
hospitalizations and CVD-related re-hospitalizations per
senior was not affected by statins use either before or after
propensity adjustment (Table 3).
Although statins decreased the number of physician visits
in older adults by 16% before propensity adjustment (RR
0.84, 95% CI 0.79-0.88), this beneficial effect was also
removed after adjustment for propensity in the model.
Statin use was associated with an 18% increase in the
number of CVD-related physician visits (95% CI 1.09-
1.29) before propensity adjustment and a 34% increase
(95% CI 1.23-1.46) after propensity adjustment (Table 3).
Coronary revascularization procedures were significantly
increased in those receiving statins before propensity
adjustment (HR 1.55, 95% CI 1.30-1.84). However, inBMC Health Services Research 2009, 9:198 http://www.biomedcentral.com/1472-6963/9/198
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contrast to the other outcome measures, including the
propensity in the model negated this increase (Table 3).
Impact of Statins on Mortality
After adjustment for clinical and demographic variables,
patients who received statins had a 59% reduction in mor-
tality compared with patients who did not receive statins
(HR 0.41, 95% CI 0.35-0.49). After the propensity score
was incorporated into the model, statins were associated
with a 26% reduction in mortality (HR 0.74, 95% CI 0.63-
0.88) (Table 3).
Discussion
This study found that older adults receiving a statin after
discharge from hospital with IHD realized significant
mortality benefits; however, reductions in re-hospitaliza-
tions, physician visits, or coronary revascularizations were
not demonstrated over the follow-up period of approxi-
mately two years.
Thirty-eight percent (38%) of older adults discharged
from hospital received statins in our study; this may seem
inconsistent with current North American guidelines
Table 2: Characteristics of 4232 Nova Scotia seniors discharged from hospital with unstable angina or myocardial infarction
Characteristic Statin Dispensed (n = 1629) No Statin Dispensed (n = 2603) p value
Demographics
Age (years) (range) 74.6 ± 5.7 (66-98 years) 79.2 ± 7.1 (66-101 years) < 0.0001
Gender (Males) 49.8% 47.1% 0.085
Risk Factors/Comorbidities
Hypertension 58.8% 58.2% 0.705
Smoking < 0.0001
Never 48.9% 57.9%
Current 18.00% 13.5%
Past 33.1% 28.6%
Family history of CVD 15.3% 8.4% < 0.0001
Diabetes 26.2% 29.0% 0.047
History of CHF 8.5% 17.6% < 0.0001
History of MI 25.8% 30.9% 0.0004
History of Stroke 6.4% 11.5% < 0.0001
History of TIA 4.5% 7.5% < 0.0001
Number of distinct prescription medications in 6 months pre-
hospitalization
5.7 ± 4.2 6.6 ± 4.6 < 0.0001
Area in Province Patient Resides 0.035
North 18.1% 17.6%
Central 35.1% 32.5%
East 21.7% 20.8%
West 25.0% 29.0%
Factors During Index Hospitalization
Discharge Diagnosis
Unstable Angina 46.0% 51.0% 0.001
Myocardial Infarction 54.0 % 49.0%
In-hospital procedures
CABG 6.0% 3.7% 0.0004
Cardiac catheterization 27.1% 15.6% < 0.0001
PTCA 10.8% 5.7% < 0.0001
EST 48.8% 25.1% < 0.0001
Concomitant medications written at hospital discharge
ASA 85.2% 75.3% < 0.0001
ACE inhibitor 46.2% 47.6% 0.375
Beta-blocker 83.1% 75.9% < 0.0001
Calcium channel blocker 37.4% 37.5% 0.950
Fibrates 6.1% 4.9% 0.0092
Cholesterol Levels measured in Hospital (Y/N)
Total cholesterol 68.1% 46.0% < 0.0001
LDL cholesterol 63.1% 42.0% < 0.0001
HDL cholesterol 50.9% 49.1% < 0.0001
Triglycerides 54.5% 45.5% < 0.0001
Factors Post-Index Hospitalization
Follow-up (# years) 2.7 ± 1.1 2.1 ± 1.2 < 0.0001
Crude Mortality 11.4% 35.9% < 0.0001BMC Health Services Research 2009, 9:198 http://www.biomedcentral.com/1472-6963/9/198
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which suggest that most patients at high-risk for CVD dis-
ease should receive treatment with these medications
regardless of age [46,47]. The low utilization of statins in
our population may be a reflection of the study period
(1997-2001), with other studies reporting utilization of
statins in older adults with established disease over this
time period describing similar prescribing rates [48-51].
This study demonstrated that older adults with increased
markers for disease severity were less likely to be dis-
pensed statins after discharge than were their healthier
counterparts. Other published studies have also shown
consistent treatment biases for the use of statins in the
older adults at highest risk for developing CVD
[37,39,48,49,52,53]. Although some published studies
have reported that females with CVD were treated less
often than their male counterparts [18,54-57], our results
agree with more recent reports that do not demonstrate
this treatment bias [48,58-60].
While there is limited data describing health service utili-
zation associated with statin use, we were somewhat sur-
prised that we did not observe a decrease in health service
utilization associated with statins similar to that seen in
randomized trials [61-63]. Many authors have postulated
various mechanisms, including plaque stabilization and
improved endothelial function [64-69] that would sup-
port the benefits of statin therapy on a variety of health
outcomes, including CVD-related events and coronary
revascularizations. However, our results are similar to
those demonstrated in two other observational studies
that examined the impact of statins on re-hospitalizations
[38,70], Perhaps more aggressive management of CVD,
reflected by prescribing of statins, results in regular ongo-
ing patient follow-up and management, leading to
increases in health services utilization.
There may be other reasons why older adults access health
services that may have little to do with ill health or with
medication utilization. A vast array of health service utili-
zation influences have been identified including societal
factors, availability of physicians and hospital beds, and
personal factors [71,72]. Many of these factors may have
impacted physician visits, re-hospitalizations and coro-
nary revascularization procedures to a greater degree than
the use of statin medications in a real-world population.
While statin therapy was associated with increases in
CVD-related re-hospitalizations and CVD-related physi-
cian visits, these increases may be correlated. Older adults
receiving statins may visit their physician for a CVD-
related cause more often than those not receiving statins
due to ongoing lipid monitoring or to receive a new statin
prescription. Due to these increases in physicians' visits,
there could be a "detection bias" in that patients that visit
their physician may be more likely to be investigated
more aggressively for chest pain and be referred to the
hospital for recurrent angina.
After adjustment for clinical and demographic variables,
statins were associated with a 26% reduction in mortality
(HR 0.74, 95% CI 0.63-0.88) after propensity adjustment.
The 26% reduction in mortality associated with statin
therapy in older adults with CVD in our study is similar to
Table 3: Hazards ratios and relative risks for the association between statins and health service utilization/mortality in 4232 Nova 
Scotia seniors discharged from hospital with unstable angina or myocardial infarction
Outcome Impact of Statins on rate of events modeled 
using Cox Proportional Hazards (HR, 95% CI) 
(Statin versus No Statin)
Impact of Statins on number of events, 
modeled using Generalized Linear Models (RR, 
95% CI) (Statin versus No Statin)
All-cause re-hospitalizations
Modeled without propensity score 0.84 (0.78-0.90) 0.97 (0.90-1.04)
Modeled with propensity score 0.98 (0.91-1.06) 1.04 (0.97-1.12)
CVD re-hospitalizations
Modeled without propensity score 0.98 (0.90-1.07) 0.90 (0.86-1.12)
Modeled with propensity score 1.11 (1.02-1.22) 1.03 (0.92-1.16)
All physician visits N/A
Modeled without propensity score 0.84 (0.79-0.88)
Modeled with propensity score 0.97 (0.92-1.02)
CVD-related physician visits N/A
Modeled without propensity score 1.18 (1.09-1.29)
Modeled with propensity score 1.34 (1.23-1.46)
Coronary Revascularizations N/A
Modeled without propensity score 1.55 (1.30-1.84)
Modeled with propensity score 1.15 (0.97-1.36)
Mortality N/A
Modeled without propensity score 0.41 (0.35-0.49)
Modeled with propensity score 0.74 (0.63-0.88)BMC Health Services Research 2009, 9:198 http://www.biomedcentral.com/1472-6963/9/198
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results demonstrated in two large randomized trials [61-
63] and in two meta-analyses [73,74] of trials in older
adults taking statins.
There have been few observational studies examining the
effect of statins on all-cause mortality in older adults with
CVD. One recent observational study of 2626 patients 65
years and older with established CVD living in nursing
homes [70] demonstrated a 31% reduction in one-year
mortality associated with statins. Nonetheless, as older
adults admitted to nursing homes often have a high acuity
of illness, it is difficult to determine if the benefits demon-
strated could be extrapolated to a community dwelling
senior population.
Three other studies [75-77] examined the use of statins in
patients discharged from hospital with CHD, with stratifi-
cation by age to determine mortality in older adults.
While significant reductions in mortality were demon-
strated (28%-60%), these studies did not incorporate pro-
pensity analysis techniques into their analysis. One other
published study has examined the impact of statins on
mortality in older adults discharged from hospital with an
AMI that incorporated propensity analysis techniques
into the analysis [78]. The authors demonstrated that dis-
charge statin therapy was associated with a decrease in 3-
year mortality similar to that found in our study (HR 0.89,
95% CI 0.83-0.96). However, mortality reductions were
not evident in those aged 80 years and older. While this
age-statin interaction was not demonstrated in our study,
this issue needs further exploration.
Several limitations of our study merit consideration. First,
statin therapy was not randomly assigned, introducing an
important source of bias into the study. Despite adjust-
ments for confounding through multivariate techniques
incorporating covariates and propensity adjustment,
residual confounding from unobserved or unmeasured
confounders cannot be excluded.
Although Canada has a universal health insurance system,
access to hospital services, physician services and cardiac
procedures has shown to vary with socioeconomic status
and across regions [79-81]. While all older adults in this
study had coverage for prescription medications through
the Nova Scotia Pharmacare Program, prescription co-
payments did increase over this study period, from 20% to
33% of each prescription. This may have affected medica-
tion access over the study period, although one recent
Canadian study disputes this theory [81]. As this study
examined older adults discharged from the hospital with
IHD, the results may not be generalizable to older adults
recruited from primary care. Finally, data was not availa-
ble on compliance with or discontinuation of statins dur-
ing the study period. An analysis of these factors may
reveal important differences in outcomes depending on
the length of time that a person receives the medication.
Nonetheless, as our study examines the impact of statin
use on health services use and mortality in all statin users,
our outcomes reflect those that occur in real-world use of
these medications.
Conclusion
Based on the results of this population-based observa-
tional study, we conclude that statins are associated with
important reductions in mortality in older adults dis-
charged from hospital with cardiovascular disease. Re-
hospitalizations and physician visits were not decreased
by statin utilization, however, the number of CVD-related
physician visits per senior, and the rate of CVD-related re-
hospitalizations were increased, a finding which requires
further exploration.
As the utilization of statins continues to grow, their
impact on the health care system will continue to be
important. Future studies are needed to continue to deter-
mine which patients should receive statins, the optimal
time from diagnosis to initiation, and strategies to ensure
that those who would receive significant benefit from
these medications receive it. Further exploration of the
relationship between statin use and health services use is
required in order to promote safe, appropriate and cost-
effective management of older adults with CVD.
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